Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.1
4.3
Journals
Pharmaceuticals
Special Issues
Advances in Drug Analysis and Drug Development
share announcement

Advances in Drug Analysis and Drug Development

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmaceutical Technology".

Deadline for manuscript submissions: closed (25 November 2024) | Viewed by 6530

Special Issue Editors

Dr. Daniela Amidžić Klarić

E-Mail Website
Guest Editor
Faculty of Pharmacy of Biochemistry, University of Zagreb, A. Kovačića 1, 10000 Zagreb, Croatia
Interests: pharmaceutical analysis; supplement analysis; sample preparation; atomic spectroscopy; chromatography; food analytical chemistry; food control; bioactive compounds; metals
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Ana Mornar

E-Mail Website
Guest Editor
Faculty of Pharmacy of Biochemistry, University of Zagreb, A. Kovačića 1, 10000 Zagreb, Croatia
Interests: drug development; sample preparation; pharmaceutical analysis; bioanalysis; biopharmaceutical analysis; food analysis; chromatography; mass spectrometry

Special Issue Information

Dear Colleagues,

The different phases of drug development include preclinical and clinical drug development. During this long-term process, a large number of different compounds (active pharmaceutical substances, excipients, impurities and metabolites) are monitored, and the development of new analytical methods facilitates the implementation.

This Special Issue of Pharmaceuticals will be a collection of research articles, short communications and reviews related to original and novel analytical methods developed for the evaluation of active substances in various dosage forms during drug development.

From the analytical point of view, a special challenge is the identification and determination of metabolites, as the products of drug metabolism, and other endogenous compounds. Green and sustainable analytical procedures are more than welcome, as well as methods, including the pre-treatment of different dosage forms and biological materials as samples.

The coverage of this Special Issue includes, but is not limited to:

  • Advances in instrumental analysis in drug development;
  • Preformulation and pharmaceutical formulation studies;
  • Preclinical and clinical evaluation of formulation technologies;
  • The pharmacokinetic analysis of active substances and metabolites;
  • Innovative processing and analytical technologies;
  • Extractable and leachable testing in pharmaceutical analysis;
  • Bioanalysis of nano-drug delivery systems;
  • Lab-on-chip technology;
  • High-throughput screening in preformulation studies;
  • Validation and regulatory aspects in pharmaceutical analysis.

We are looking forward to hearing from you.

Dr. Daniela Amidžić Klarić
Prof. Dr. Ana Mornar
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • analytical methodology

  • chromatographic techniques
  • spectrometric techniques
  • thermal analysis techniques
  • sample preparation
  • drug stability
  • compatibility study
  • bioavailability studies
  • therapeutic drug monitoring
  • quality by design in pharmaceutical analysis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (5 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 1411 KiB  
Article
Effect of Citric Acid and Tromethamine on the Stability of Eyedrops Containing Lifitegrast
by Ji-Su Jeong, Eun-Sol Ha, Heejun Park, Seon-Kwang Lee, Hui-Taek Kang and Min-Soo Kim
Pharmaceuticals 2024, 17(11), 1415; https://doi.org/10.3390/ph17111415 - 23 Oct 2024
Viewed by 663
Abstract
Background/Objectives: Lifitegrast is an effective treatment for dry eye disease, reducing inflammation and improving the ocular surface condition. Owing to its high sensitivity to oxidation and hydrolysis, formulation studies are required to maintain the physicochemical stability of lifitegrast. This study aimed to overcome [...] Read more.
Background/Objectives: Lifitegrast is an effective treatment for dry eye disease, reducing inflammation and improving the ocular surface condition. Owing to its high sensitivity to oxidation and hydrolysis, formulation studies are required to maintain the physicochemical stability of lifitegrast. This study aimed to overcome the instability of lifitegrast by developing a more stable eyedrop formulation by using citric acid and tromethamine to prevent the degradation of lifitegrast. Methods: Based on the Design of Experiment (DoE) approach, formulations were prepared at various concentrations of two stabilizers, citric acid and tromethamine. The stabilizers were carefully controlled to reduce the generation of degradation products. The eyedrops were stored under accelerated test conditions, and parameters such as appearance, pH, drug content, and impurities were evaluated. Results: The results showed that all critical quality attributes (CQAs) including appearance, pH, drug content, and impurities were maintained at stable levels under accelerated conditions, meeting established criteria. In addition, it was suggested that citric acid provided protection against oxidative stress, while tromethamine prevented hydrolysis caused by pH fluctuations. Conclusions: Consequently, it was concluded that the developed lifitegrast-containing eyedrop formulation exhibited improved physicochemical stability, validated through statistical analyses. These findings contribute to the development of stable eyedrops and provide a foundation for commercial production and clinical applications. Full article
(This article belongs to the Special Issue Advances in Drug Analysis and Drug Development)
►▼ Show Figures

Graphical abstract

17 pages, 11924 KiB  
Article
Auranofin as a Novel Anticancer Drug for Anaplastic Thyroid Cancer
by Seung-Chan An, Hak Hoon Jun, Kyeong Mi Kim, Issac Kim, Sujin Choi, Hyunjeong Yeo, Soonchul Lee and Hyun-Ju An
Pharmaceuticals 2024, 17(10), 1394; https://doi.org/10.3390/ph17101394 - 18 Oct 2024
Viewed by 958
Abstract
Background/Objectives: Anaplastic thyroid cancer (ATC) is an aggressive and rare cancer with a poor prognosis, and traditional therapies have limited efficacy. This study investigates drug repositioning, focusing on auranofin, a gold-based drug originally used for rheumatoid arthritis, as a potential treatment for ATC. [...] Read more.
Background/Objectives: Anaplastic thyroid cancer (ATC) is an aggressive and rare cancer with a poor prognosis, and traditional therapies have limited efficacy. This study investigates drug repositioning, focusing on auranofin, a gold-based drug originally used for rheumatoid arthritis, as a potential treatment for ATC. Methods: Auranofin was identified from an FDA-approved drug library and tested on two thyroid cancer cell lines, 8505C and FRO. Antitumor efficacy was evaluated through gene and protein expression analysis using Western blot, FACS, and mRNA sequencing. In vivo experiments were conducted using subcutaneous injections in nude mice to confirm the anticancer effects of auranofin. Results: Auranofin induced reactive oxygen species (ROS) production and apoptosis, leading to a dose-dependent reduction in cell viability, G1/S phase cell cycle arrest, and altered expression of regulatory proteins. It also inhibited cancer stem cell activity and suppressed epithelial–mesenchymal transition. mRNA sequencing revealed significant changes in the extracellular matrix–receptor interaction pathway, supported by Western blot results. In vivo xenograft models demonstrated strong antitumor activity. Conclusions: Auranofin shows promise as a repurposed therapeutic agent for ATC, effectively inhibiting cell proliferation, reducing metastasis, and promoting apoptosis. These findings suggest that auranofin could play a key role in future ATC treatment strategies. Full article
(This article belongs to the Special Issue Advances in Drug Analysis and Drug Development)
►▼ Show Figures

Figure 1

21 pages, 598 KiB  
Article
RP-CAD for Lipid Quantification: Systematic Method Development and Intensified LNP Process Characterization
by Nicole Beckert, Annabelle Dietrich and Jürgen Hubbuch
Pharmaceuticals 2024, 17(9), 1217; https://doi.org/10.3390/ph17091217 - 16 Sep 2024
Viewed by 1191
Abstract
Lipid nanoparticles (LNPs) and their versatile nucleic acid payloads bear great potential as delivery systems. Despite their complex lipid composition, their quality is primarily judged by particle characteristics and nucleic acid encapsulation. In this study, we present a holistic reversed-phase (RP)-charged aerosol detection [...] Read more.
Lipid nanoparticles (LNPs) and their versatile nucleic acid payloads bear great potential as delivery systems. Despite their complex lipid composition, their quality is primarily judged by particle characteristics and nucleic acid encapsulation. In this study, we present a holistic reversed-phase (RP)-charged aerosol detection (CAD)-based method developed for commonly used LNP formulations, allowing for intensified LNP and process characterization. We used an experimental approach for power function value (PFV) optimization termed exploratory calibration, providing a single PFV (1.3) in an appropriate linearity range for all six lipids. Followed by the procedure of method calibration and validation, linearity (10–400 ng, R2 > 0.996), precision, accuracy, and robustness were effectively proven. To complement the commonly determined LNP attributes and to evaluate the process performance across LNP processing, the developed RP-CAD method was applied in a process parameter study varying the total flow rate (TFR) during microfluidic mixing. The RP-CAD method revealed a constant lipid molar ratio across processing but identified deviations in the theoretical lipid content and general lipid loss, which were both, however, entirely TFR-independent. The deviations in lipid content could be successfully traced back to the lipid stock solution preparation. In contrast, the observed lipid loss was attributable to the small-scale dialysis following microfluidic mixing. Overall, this study establishes a foundation for employing RP-CAD for lipid quantification throughout LNP processing, and it highlights the potential to extend its applicability to other LNPs, process parameter studies, or processes such as cross-flow filtration. Full article
(This article belongs to the Special Issue Advances in Drug Analysis and Drug Development)
►▼ Show Figures

Graphical abstract

21 pages, 4899 KiB  
Article
Development of Analytical Method for the Quantitation of Monoclonal Antibodies Solutions via Raman Spectroscopy: The Case of Bevacizumab
by Michail Lykouras, Panagiota Papaspyridakou, Olga E. Makri, Constantine D. Georgakopoulos and Malvina G. Orkoula
Pharmaceuticals 2024, 17(4), 446; https://doi.org/10.3390/ph17040446 - 29 Mar 2024
Viewed by 1277
Abstract
Personalized dosages of monoclonal antibodies are being used more regularly to treat various diseases, rendering their quantitation more essential than ever for the right dose administration to the patients. A promising alternative, which overcomes the obstacles of the well-established chromatographic techniques regarding the [...] Read more.
Personalized dosages of monoclonal antibodies are being used more regularly to treat various diseases, rendering their quantitation more essential than ever for the right dose administration to the patients. A promising alternative, which overcomes the obstacles of the well-established chromatographic techniques regarding the quantification of biopharmaceuticals, is Raman spectroscopy. This study aimed to develop and validate a novel analytical method for the quantitation of bevacizumab in solutions via Raman spectroscopy. For this purpose, a droplet of the solution was left to dry on a highly reflective carrier and a home-made apparatus was employed for rotation of the sample. Hence, each recorded Raman spectrum was the average of the signal acquired simultaneously from multiple points on a circular circumference. The method was validated, and the detection limit of the antibody was found to be 1.06 mg/mL. Bevacizumab was found to be highly distributed at the formed coffee ring of the dried droplet, though this was a function of solution concentration. Finally, Raman spectra at different distances on the coffee ring were obtained from the four quarters. The lowest bevacizumab detection limit was found at a distance of 75 μm from the external side of the coffee ring and it was determined to be equal to 0.53 mg/mL. Full article
(This article belongs to the Special Issue Advances in Drug Analysis and Drug Development)
►▼ Show Figures

Figure 1

19 pages, 3273 KiB  
Article
The Study on Timolol and Its Potential Phototoxicity Using Chemical, In Silico and In Vitro Methods
by Karolina Lejwoda, Anna Gumieniczek, Agata Filip and Beata Naumczuk
Pharmaceuticals 2024, 17(1), 98; https://doi.org/10.3390/ph17010098 - 11 Jan 2024
Cited by 1 | Viewed by 1535
Abstract
Timolol (TIM) is a non-selective ß-adrenergic receptor antagonist used orally for the treatment of hypertension and heart attacks, and topically for treating glaucoma; lately, it has also been used in some specific dermatological problems. In the present study, its photodegradation and potential risk [...] Read more.
Timolol (TIM) is a non-selective ß-adrenergic receptor antagonist used orally for the treatment of hypertension and heart attacks, and topically for treating glaucoma; lately, it has also been used in some specific dermatological problems. In the present study, its photodegradation and potential risk of phototoxicity were examined using chemical, in silico and in vitro methods. The UV/VIS irradiated solutions of TIM at pH 1–13 were subjected to LC-UV and UPLC-HRMS/MS analyses showing pseudo first-order kinetics of degradation and several degradation products. The structures of these photodegradants were elucidated by fragmentation path analysis based on high resolution (HR) fragmentation mass spectra, and then used for toxicity evaluation using OSIRIS Property Explorer and Toxtree. Potential risk of phototoxicity was also studied using chemical tests for detecting ROS under UV/VIS irradiation and in vitro tests on BALB/c 3T3 mouse fibroblasts (MTT, NRU and Live/Dead tests). TIM was shown to be potentially phototoxic because of its UV/VIS absorptive properties and generation ROS during irradiation. As was observed in the MTT and NRU tests, the co-treatment of fibroblasts with TIM and UV/VIS light inhibited cell viability, especially when concentrations of the drug were higher than 50 µg/mL. Full article
(This article belongs to the Special Issue Advances in Drug Analysis and Drug Development)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-5
Back to TopTop